GILD

GILEAD SCIENCES, INC.

Gilead Sciences develops medicines for viral diseases, cancer and inflammatory conditions.

Company website ↗

Upcoming catalysts

Next 30 days
View 15 more events
  • Dec 12, 2026
    Yescarta (axicabtagene ciloleucel)

    Phase 2 data

    Company source ↗
  • Dec 12, 2026
    Yescarta (axicabtagene ciloleucel)

    Data readout

    Company source ↗
  • Dec 12, 2026
    Yescarta (axicabtagene ciloleucel)

    Data readout

    Company source ↗
  • Dec 13, 2026
    Anito-cel — fourth-line or later multiple myeloma

    Data readout

    Company source ↗
  • Dec 13, 2026
    Anito-cel — fourth-line or later multiple myeloma

    Data readout

    Company source ↗
  • December 13, 2026 — bridging irradiation before axi-cel presentation
    Yescarta (axicabtagene ciloleucel)

    Conference presentation

    Company source ↗
  • Dec 13, 2026
    Yescarta (axicabtagene ciloleucel)

    Phase 1 data

    Company source ↗
  • Dec 13, 2026
    om336

    Phase 1 data

    Company source ↗
  • December 14, 2026 — GELTAMO LATE-R second interim analysis
    Yescarta (axicabtagene ciloleucel)

    Phase 2 data

    Company source ↗
  • Dec 14, 2026
    KITE-753

    Phase 1 data

    Company source ↗
  • Dec 14, 2026
    Tecartus (brexucabtagene autoleucel)

    Conference presentation

    Company source ↗
  • ASH 2026, December 12–15; session date unspecified
    Yescarta (axicabtagene ciloleucel)

    Data readout

    Company source ↗
  • Second CD19-directed CAR T-cell outcomes at ASH 2026, December 12–15
    Tecartus (brexucabtagene autoleucel)

    Data readout

    Company source ↗
  • Rocca consortium CML analysis at ASH 2026, December 12–15
    Tecartus (brexucabtagene autoleucel)

    Data readout

    Company source ↗
  • Extramedullary B-ALL analysis at ASH 2026, December 12–15
    Tecartus (brexucabtagene autoleucel)

    Data readout

    Company source ↗

Company workspace

Clinical pipeline

Programs, trial stages and evidence

Member access →

Stock & financials

Financial reports and ownership

Member access →